Drugs / iGlar
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07274644 | Mar 2025 → Jun 2026 overdue | metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iGlar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07274644 ↗ |
| Known as | IGlar U100 | “Drug: IGlar U100” NCT07274644 ↗ |
| Route | Subcutaneous | “The iGlar is administered via subcutaneous injection” NCT07274644 ↗ |